Johnson & Johnson (SNSE:JNJCL)
Chile · Delayed Price · Currency is CLP | Market Cap | 620.06T +49.2% |
| Revenue (ttm) | 90.34T +8.1% |
| Net Income | 19.41T -7.2% |
| EPS | 7,958.72 -7.6% |
| Shares Out | n/a |
| PE Ratio | 31.95 |
| Forward PE | 23.78 |
| Dividend | 4,770.77 (1.91%) |
| Ex-Dividend Date | Aug 25, 2026 |
| Volume | n/a |
| Open | n/a |
| Previous Close | 249,730 |
| Day's Range | n/a |
| 52-Week Range | 166,900 - 250,900 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 13, 2026 |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription... [Read more]
Financial Performance
In 2025, Johnson & Johnson's revenue was $94.19 billion, an increase of 6.05% compared to the previous year's $88.82 billion. Earnings were $26.80 billion, an increase of 90.56%.
Financial numbers in USD Financial StatementsNews
Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026
First presentation of pivotal Phase 3 CAPLYTA ® data in adults with bipolar mania underscores the asset's potential across mood disorders New SPRAVATO ® analyses and schizophrenia research emphasize a...
Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Deutsche Bank 2026 Healthcare Summit on Thursday, September 17th, 2026. Management will participate in a Firesid...
Johnson & Johnson assumed with a Buy at UBS
UBS assumed coverage of Johnson & Johnson with a Buy rating and a price target of $320, up from $280, based on new, higher above-consensus estimates. The analyst is “bullish…
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 13th to review third-quarter results. Joaq...
China approves J&J's oral psoriasis pill, says drugmaker
China's drug regulator has approved Johnson & Johnson's oral pill for psoriasis, the company said on Thursday, intensifying competition in the world's second-largest pharmaceutical market with riva...
FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients
IMAAVY is an immunoselective FcRn blocker designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies while also preserving B-cell function Warm autoimmune hemolytic anemia is a rar...
US FDA expands approval for J&J's drug for rare blood disorder
The U.S. Food and Drug Administration has approved the expanded use of Johnson & Johnson's drug to treat a rare blood disorder, the company said on Monday.
Louisiana Jury Issues $10 Million Verdict in Talc-Related Mesothelioma Case Against Johnson & Johnson
DALLAS--(BUSINESS WIRE)--Texas trial law firm Dean Omar Branham Shirley, LLP (DOBS) has secured a $10 million jury verdict in a mesothelioma case brought on behalf of the family of Lynne Roy, a Louisi...
Analysts Back Dividend Aristocrats JNJ and LIN Ahead of Q3 Earnings
Johnson & Johnson ($JNJ) and Linde ($LIN) are two of the dividend aristocrat stocks rated Strong Buy by analysts covering the stocks, according to TipRanks’ Dividend Aristocrat tool. Johnson &…
Oppenheimer upgrades Intuitive Surgical on lack of U.S. competition
Oppenheimer upgraded Intuitive Surgical (ISRG) to Outperform from Perform with a $500 price target. Field checks suggest workflow challenges for Johnson & Johnson’s (JNJ) Ottava that limit long-term a...
Expert explains why healthcare is a top-performing sector
Apollon Wealth Management CIO Eric Sterner discusses how technology is driving gains in the healthcare sector on ‘The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbus...
Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14th, 2026. Management will partici...
Jim Cramer highlights 5 investing themes — and the stocks to buy for each
CNBC's Jim Cramer said earnings season reinforced five investing themes he thinks will produce the market's best buying opportunities. He highlighted stocks to buy for each theme, including Capital On...
Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the 2026 Wells Fargo Healthcare Conference on Wednesday, September 9th, 2026. Management will participate in a Fires...
Johnson & Johnson's Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that Jennifer Taubert will retire from her position as Executive Vice President, Worldwide Chairman, Innovative Medi...
Johnson & Johnson Transcript: Investor update
OTTAVA launches as a table-integrated robotic surgery platform, targeting expansion in the U.S. and globally with a differentiated design, automation, and digital ecosystem. Early clinical results show strong workflow and efficiency benefits, with a roadmap for rapid indication and instrument expansion.
Inside J&J's Lab to Create a Simpler Robotic Surgery Device
After spending years and hundreds of millions of dollars, Johnson and Johnson has won FDA approval for its new surgical robot Ottava. Can it challenge the dominance of competitors who entered the race...
Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer
Priority Review reinforces the significant potential of subcutaneous amivantamab in recurrent or metastatic head and neck cancer, where the current five-year survival rate is only 15 percent Patients...
Johnson & Johnson Comes to Strategic Agreement with Sail Biomedicines
Under the agreement, Johnson & Johnson would make total initial payments of $785 million, and has the exclusive option to acquire Sail for $2.58 billion.
Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced the successful completion of its acquisition of Firefly Bio, Inc., a biotechnology company advancing its proprietary...
Johnson & Johnson lowers 2026 profit forecast
Johnson & Johnson cut 2026 profit forecast on Wednesday, citing the combined financial impact of its newly completed acquisition of Firefly Bio and a strategic partnership with Sail Biomedici...
Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson1 (NYSE: JNJ) today announced strategic agreements and collaboration with Sail Biomedicines (Sail), a biotechnology company developing in vivo CA...
Explainer: Can J&J finally put the talc litigation behind it?
After years of failed attempts to resolve thousands of lawsuits alleging that its talc products caused cancer, Johnson & Johnson says it has reached a settlement, worth at least $5.5 billion, that cou...
Johnson & Johnson offers $5.5 billion to settle remaining lawsuits over talc products linked to cancer
Johnson & Johnson has agreed to pay $5.5 billion to tie up remaining lawsuits that claim its talc products caused ovarian cancer.
Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits
Johnson & Johnson says it will pay an estimated $5.5 billion to settle about 76,000 lawsuits alleging its baby powder and talc caused ovarian cancer.